All segments of healthcare will need to adapt to unprecedented change driven by technological advancements in areas such as molecular biology, AI and digitalization
BOSTON--(BUSINESS WIRE)-- As pivotal changes in healthcare and drug development gain traction, new analysis from Arthur D. Little (ADL) highlights that all sectors of the industry must evolve their business and operating models in the coming decade.
From genomic treatments to Artificial Intelligence in diagnostics to leaps in curative medicine, the healthcare ecosystem is facing unprecedented change. ADL’s forward-looking assessment is captured in a new Report, “Future Health: How the industry will move from ‘one size fits all’ to ultra-targeted care.”
Several critical shifts are pushing major players across the world to adapt:
Craig Wylie, Managing Partner at ADL in the United States, notes: “Incredible advances in genomics and diagnostics are leading to a future that will impact the entire breadth of the healthcare industry. Companies are in the early stages of evolving their approach to clinical trials, commercial models, and care provision.”
“The pace of change and the associated costs will be staggering,” continued Wylie. “The most successful organizations across all segments of the healthcare ecosystem will be those that adapt their business models, rethink their operations, and place an emphasis on collaboration and partnerships.”
To download the Report, please visit: www.adl.com/FutureHealth
Contacts
Cate Bonthuys
Catalyst Comms
cate@catalystcomms.co.uk
Tel: +44 7746546773
财华网所刊载内容之知识产权为财华网及相关权利人专属所有或持有。未经许可,禁止进行转载、摘编、复制及建立镜像等任何使用。
如有意愿转载,请发邮件至content@finet.com.hk,获得书面确认及授权后,方可转载。
更多精彩内容,请登陆
财华香港网(https://www.finet.hk/)
财华智库网(https://www.finet.com.cn)
现代电视(http://www.fintv.hk)